lestaurtinib has been researched along with leuprolide in 1 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (leuprolide) | Trials (leuprolide) | Recent Studies (post-2010) (leuprolide) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 3,082 | 777 | 772 |
| Protein | Taxonomy | lestaurtinib (IC50) | leuprolide (IC50) |
|---|---|---|---|
| Gonadotropin-releasing hormone receptor | Homo sapiens (human) | 0.0005 | |
| Gonadotropin-releasing hormone receptor | Rattus norvegicus (Norway rat) | 0.0006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angeles, T; Dionne, CA; George, DJ; Isaacs, JT; Jani, J; Lamb, J; Murakata, C | 1 |
1 other study(ies) available for lestaurtinib and leuprolide
| Article | Year |
|---|---|
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carbazoles; Combined Modality Therapy; Drug Screening Assays, Antitumor; Drug Synergism; Furans; Indoles; Injections, Subcutaneous; Leuprolide; Male; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins; Rats; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptors, Nerve Growth Factor | 1999 |